Cabaletta Bio, Inc. (CABA)
- Previous Close
13.32 - Open
13.46 - Bid 12.92 x 600
- Ask 12.98 x 600
- Day's Range
12.90 - 13.67 - 52 Week Range
7.77 - 26.35 - Volume
738,298 - Avg. Volume
970,732 - Market Cap (intraday)
625.308M - Beta (5Y Monthly) 2.41
- PE Ratio (TTM)
-- - EPS (TTM)
-1.65 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.11
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
www.cabalettabio.comRecent News: CABA
Performance Overview: CABA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CABA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CABA
Valuation Measures
Market Cap
642.68M
Enterprise Value
406.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.18%
Return on Equity (ttm)
-39.72%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-67.67M
Diluted EPS (ttm)
-1.65
Balance Sheet and Cash Flow
Total Cash (mrq)
241.25M
Total Debt/Equity (mrq)
2.12%
Levered Free Cash Flow (ttm)
-30.41M